JPM 2024 Roundup: Abbott And Medtronic Push Diabetes Tech, Edwards Updates Tricuspid Progress, Shockwave Bets On R&D
Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.
Abbott expects sales of its successful FreeStyle Libre line of continuous glucose monitoring (GCM) systems to be worth $10bn in revenue annually by 2028.
The company expects Libre sales to reach nearly $5bn this year. (Also see "Dexcom Tries To Close Gap On...